Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145376

Pw145376 View Pathway
drug action

Cefonicid Drug Metabolism Action Pathway

Homo sapiens

PW175993

Pw175993 View Pathway
metabolic

Cefonicid Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Cefonicid are predicted with biotransformer.

PW176944

Pw176944 View Pathway
drug action

Cefoperazone Action Pathway

Escherichia coli
Cefoperazone is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections in various locations, including the respiratory tract, abdomen, skin, and female genital tracts. Cefoperazone exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs). Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW145377

Pw145377 View Pathway
drug action

Cefoperazone Drug Metabolism Action Pathway

Homo sapiens

PW175994

Pw175994 View Pathway
metabolic

Cefoperazone Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Cefoperazone are predicted with biotransformer.

PW176958

Pw176958 View Pathway
drug action

Ceforanide Action Pathway

Escherichia coli
Ceforanide is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics.5 It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections. Ceforanide exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs).5 In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3.5 Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.

PW145024

Pw145024 View Pathway
drug action

Ceforanide Drug Metabolism Action Pathway

Homo sapiens

PW175995

Pw175995 View Pathway
metabolic

Ceforanide Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Ceforanide are predicted with biotransformer.

PW126769

Pw126769 View Pathway
drug action

Cefotaxime Action Pathway

Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Cefotaxime is a third-generation cephalosporin used to treat susceptible gram-negative and gram-positive bacterial infections. It is used to treat gonorrhea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery. action The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Penicillin binding proteins are responsible for glycosyltransferase and transpeptidase reactions that lead to cross-linking of D-alanine and D-aspartic acid in bacterial cell walls. Inhibition of this protein leads to upregulation of autolytic enzymes and inhibition of cell wall synthesis. Cefotaxime is bactericidal and kills off the bacteria that it affects.

PW144615

Pw144615 View Pathway
drug action

Cefotaxime Drug Metabolism Action Pathway

Homo sapiens